NBE-Therapeutics
News/ News/ Oncology/ Top stories
Exelixis doubles down on ADCs for cancer with NBE, Catalent deals
Phil Taylor
antibody-drug conjugate, Catalent, Exelixis, licensing, NBE-Therapeutics, Oncology
0 Comment
X
Exelixis doubles down on ADCs for cancer with NBE, Catalent deals
https://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/